0001193125-22-189131.txt : 20220707 0001193125-22-189131.hdr.sgml : 20220707 20220707093532 ACCESSION NUMBER: 0001193125-22-189131 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220630 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220707 DATE AS OF CHANGE: 20220707 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLASE, INC CENTRAL INDEX KEY: 0000811240 STANDARD INDUSTRIAL CLASSIFICATION: DENTAL EQUIPMENT & SUPPLIES [3843] IRS NUMBER: 870442441 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36385 FILM NUMBER: 221070793 BUSINESS ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 BUSINESS PHONE: 949-361-1200 MAIL ADDRESS: STREET 1: 27042 TOWNE CENTRE DRIVE STREET 2: SUITE 270 CITY: FOOTHILL RANCH STATE: CA ZIP: 92610 FORMER COMPANY: FORMER CONFORMED NAME: BIOLASE TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER MEDICAL TECHNOLOGY INC DATE OF NAME CHANGE: 19941117 FORMER COMPANY: FORMER CONFORMED NAME: LASER ENDO TECHNIC CORP DATE OF NAME CHANGE: 19920708 8-K 1 d364747d8k.htm 8-K 8-K
BIOLASE, INC false 0000811240 0000811240 2022-06-30 2022-06-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2022

 

 

BIOLASE, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-36385   87-0442441

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

27042 Towne Centre Drive,

Suite 270

    
Lake Forest, California     92610
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 361-1200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   BIOL  

The NASDAQ Stock Market LLC

(NASDAQ Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.01.

Entry into a Material Definitive Agreement.

On June 30, 2022, BIOLASE, Inc., a Delaware corporation (the “Company”), entered into the Ninth Amendment to Credit Agreement (the “Ninth Amendment”) with SWK Funding LLC (“SWK”), in connection with that certain Credit Agreement (the “Credit Agreement”), by and among the Company, SWK, and the lender parties thereto. The Ninth Amendment amends the Credit Agreement by extending the end of the interest only period of the loan by two quarters, from May 2023 to November 2023, reducing the required minimum consolidated unencumbered liquid assets from $7,500,000 to $3,000,000, reducing the minimum consolidated unencumbered liquid assets triggering the minimum aggregate revenue covenant from $7,500,000 to $5,000,000, and reducing the minimum consolidated unencumbered liquid assets triggering the minimum EBITDA covenant from $7,500,000 to $5,000,000. In connection with the Ninth Amendment, the Company prepaid $1,000,000 of the outstanding loan balance. The Ninth Amendment contains representations, warranties, covenants, releases, and conditions customary for a credit agreement amendment of this type.

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 6, 2022, the Board of Directors (the “Board”) of the Company appointed Jennifer Bright as Chief Financial Officer of the Company. Ms. Bright will receive an annual salary of $285,000 in consideration for her service as Chief Financial Officer of the Company, and will be eligible for a bonus compensation target of fifty percent (50%) of annual salary, subject to criteria as established by the Compensation Committee of the Board (the “Compensation Committee”). Ms. Bright’s employment with the Company is at-will. From April 2021 until her appointment as Chief Financial Officer, Ms. Bright was the Company’s Vice President of Finance and Accounting Director. Ms. Bright, 51, is a certified public accountant with more than 25 years of professional accounting and finance experience. From June 2020 to January 2021 she was consulting as Interim Director of Accounting at Spectrum Pharmaceuticals and as Corporate Controller at Kellermeyer Bergensons Services from November 2018 to April 2020. Previously, Ms. Bright held senior accounting and controller positions at Lyon Living, Crunch Holdings, April Healthcare, and Richmond America Homes, and was a Supervising Senior Auditor at the accounting firm of PricewaterhouseCoopers LLP. Ms. Bright holds a B.A. degree in Business Administration from the University of Washington. There is no arrangement or understanding pursuant to which Ms. Bright was selected as Chief Financial Officer, and there are no related party transactions between the Company and Ms. Bright reportable under Item 404(a) of Regulation S-K.

On July 6, 2022, the Board appointed Steven Sandor as Chief Operating Officer of the Company. Mr. Sandor will receive an annual salary of $275,000 in consideration for his service as Chief Operating Officer of the Company, and will be eligible for a bonus compensation target of forty five percent (45%) of annual salary, subject to criteria as established by the Compensation Committee. Mr. Sandor’s employment with the Company is at-will. Mr. Sandor, 42, is a sales executive with more than 14 years of professional experience in the dental industry. From April 2019 until his appointment as Chief Operating Officer, Mr. Sandor served in several positions of increasing responsibility at the Company, and was most recently Senior Director of Commercial Operations and Service. From October 2016 to April 2019 he was Director of Global Training at KaVo Kerr and from May 2014 to May 2016 he was Sales Development Manager. Previously, Mr. Sandor held managerial positions at Sybron Endo, Sybron Orascoptic and AT&T, and served in the United States Coast Guard. Mr. Sandor holds an Executive Masters in Business Administration from Chapman University. There is no arrangement or understanding pursuant to which Mr. Sandor was selected as Chief Operating Officer, and there are no related party transactions between the Company and Mr. Sandor reportable under Item 404(a) of Regulation S-K.

 

Item 7.01

Regulation FD Disclosure.

On June 30, 2022, the Company issued a press release announcing the Ninth Amendment with SWK, and on July 7, 2022 the Company issued a press release announcing the appointments of Ms. Bright and Mr. Sandor, copies of which are attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.

   

Description of Exhibits

99.1    Press Release of BIOLASE, Inc, dated June 30, 2022.
99.2    Press Release of BIOLASE, Inc., dated July 7, 2022.
104    Cover page Interactive data file (embedded with in the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    BIOLASE, INC.
Date: July 7, 2022     By  

/s/ John R. Beaver

    Name:   John R. Beaver
    Title:   President and Chief Executive Officer
 EX-99.1 2 d364747dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

BIOLASE ENTERS INTO FAVORABLE CREDIT AGREEMENT AMENDMENT

LAKE FOREST, Calif., June 30, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced that, on June 30, 2022, it entered into an amendment to its senior secured term loan with SWK Funding LLC. The amendment extends the interest-only period of the loan by two quarters to November 2023 and reduces the minimum Consolidated Unencumbered Liquid Assets from $7,500,000 to $5,500,00. BIOLASE used a portion of the proceeds from its recent equity offering to prepay $1,000,000 of the outstanding loan balance.

“The recent equity offering allowed us to prepay a portion of our senior secured term loan,” commented John Beaver, President and Chief Executive Officer of BIOLASE. “This prepayment and amendment will result in lower interest expense while also increasing the Company’s liquidity.”

“Biolase continues to bring leading dental laser solutions to dentists and patients. SWK remains a supportive partner of the company and its mission,” commented Winston Black, Chief Executive Officer of SWK Holdings.

SWK Funding LLC is a subsidiary of SWK Holdings Corporation, a Dallas, Texas-based healthcare focused investment firm.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

Investor Relations:

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

EX-99.2 3 d364747dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

BIOLASE ANNOUNCES PROMOTIONS OF KEY TEAM MEMBERS

LAKE FOREST, Calif., July 7, 2022 – BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today the appointments of Jennifer Bright to Chief Financial Officer (“CFO”) and Steven Sandor to Chief Operating Officer (“COO”). These promotions are effective immediately, and the positions will report to John Beaver, BIOLASE’s President and Chief Executive Officer.

Bright has served as the company’s Vice President of Finance since April 2021. Bright’s responsibilities as CFO will include the functional areas of finance, accounting, investor relations, and assisting the executive management team in establishing long-range goals, strategies, plans and policies that drive positive results. Bright earned her Bachelor of Arts in Business Administration degree in accounting from the University of Washington in Seattle, Washington then began her career at PricewaterhouseCoopers and is an active Certified Public Accountant in California.

“Jennifer is a highly valuable financial professional who has demonstrated strong leadership across the breadth of our business,” commented John Beaver. “I’m very excited to further leverage Jennifer’s robust experience in corporate finance and accounting as we achieve BIOLASE’s mission and execute on our long-term strategy.”

“I look forward to serving as BIOLASE’s CFO and collaborating with our talented teams across the company to drive our continued commercial success, engage with the investment community, and serve our customers, as well as the patients and families who benefit from improved dental care with the use of BIOLASE’s advanced laser technology,” said Jennifer Bright.

Sandor joined BIOLASE in early 2019 and has served in several impactful positions in our customer-facing organizations, most recently as the company’s Senior Director of Commercial Operations and Service. Sandor has been instrumental in developing long-term strategic growth initiatives focused on leveraging talent, building robust commercial processes, and scalability. Sandor earned an Executive Master of Business Administration degree from Chapman University in Orange, California.

“Steven is a customer-focused sales and service leader who has demonstrated an exceptional ability to improve processes and drive results,” commented John Beaver. “Reporting to Steven will be the company’s sales, marketing, service, manufacturing, and distribution organizations. With Steven’s guidance and the high-performing leaders and team members reporting to him, I am confident this structure will bring even stronger communication, collaboration, and alignment across these key functions, resulting in our continued commercial success. As part of this new structure, we will also increase our focus on the highly important Dental Service Organization (DSO) market.”

“As COO, I am very excited to work with many strong BIOLASE leaders, as well as their teams, to leverage their strengths, insights, and experiences. I am confident that the combined effect of their talent, complementary business strategies and even greater collaboration will increase our capabilities and enable us to achieve higher levels of revenue, service, production, and, ultimately, market adoption of our laser technology. I look forward to our making BIOLASE lasers the gold standard of care in dentistry,” said Sandor.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE’s products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide

biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “continue,” “expect,” “believe,” “anticipate,” “estimate,” “predict,” “outlook,” “potential,” “plan,” “seek,” and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:

EVC Group LLC

Michael Polyviou / Todd Kehrli

(732) 933-2754

mpolyviou@evcgroup.com / tkehrli@evcgroup.com

EX-101.SCH 4 biol-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 biol-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 biol-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jun. 30, 2022
Cover [Abstract]  
Entity Registrant Name BIOLASE, INC
Amendment Flag false
Entity Central Index Key 0000811240
Document Type 8-K
Document Period End Date Jun. 30, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-36385
Entity Tax Identification Number 87-0442441
Entity Address, Address Line One 27042 Towne Centre Drive
Entity Address, Address Line Two Suite 270
Entity Address, City or Town Lake Forest
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92610
City Area Code (949)
Local Phone Number 361-1200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d364747d8k_htm.xml IDEA: XBRL DOCUMENT 0000811240 2022-06-30 2022-06-30 BIOLASE, INC false 0000811240 8-K 2022-06-30 DE 001-36385 87-0442441 27042 Towne Centre Drive Suite 270 Lake Forest CA 92610 (949) 361-1200 false false false false Common Stock, par value $0.001 per share BIOL NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d364747d8k.htm biol-20220630.xsd biol-20220630_lab.xml biol-20220630_pre.xml d364747dex991.htm d364747dex992.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d364747d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d364747d8k.htm" ] }, "labelLink": { "local": [ "biol-20220630_lab.xml" ] }, "presentationLink": { "local": [ "biol-20220630_pre.xml" ] }, "schema": { "local": [ "biol-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "biol", "nsuri": "http://www.biolase.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d364747d8k.htm", "contextRef": "duration_2022-06-30_to_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d364747d8k.htm", "contextRef": "duration_2022-06-30_to_2022-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biolase.com//20220630/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-189131-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-189131-xbrl.zip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